cyc 202 has been researched along with nutlin-3a in 6 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (nutlin-3a) | Trials (nutlin-3a) | Recent Studies (post-2010) (nutlin-3a) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 698 | 1 | 504 |
| Protein | Taxonomy | cyc 202 (IC50) | nutlin-3a (IC50) |
|---|---|---|---|
| Protein Mdm4 | Homo sapiens (human) | 4.6273 | |
| Cellular tumor antigen p53 | Homo sapiens (human) | 1.0388 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.07 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.1832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brongel, K; Czarna, A; Holak, TA; Kowalska, K; Orth, M; Popowicz, GM; Rothweiler, U; Stemmann, O; Weber, L | 1 |
| Boix, J; Meijer, L; Ribas, J | 1 |
| Cheok, CF; Dey, A; Lane, DP | 1 |
| Abolmaali, ND; Tokalov, SV | 1 |
| Rolfes, S; Schierwater, B; von der Chevallerie, K | 1 |
| Alexiou, P; Fojtík, P; Growková, K; Hejret, V; Jorda, R; Kryštof, V; Palušová, V; Rotrekl, V; Štětková, M; Uldrijan, S; Valčíková, B; Verlande, A | 1 |
6 other study(ies) available for cyc 202 and nutlin-3a
| Article | Year |
|---|---|
NMR screening for lead compounds using tryptophan-mutated proteins.
Topics: Cyclin-Dependent Kinase 2; Drug Evaluation, Preclinical; Humans; Lead; Ligands; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Organometallic Compounds; Point Mutation; Protein Interaction Mapping; Proteins; Proto-Oncogene Proteins c-mdm2; Structure-Activity Relationship; Tryptophan; Tumor Suppressor Protein p53 | 2008 |
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Enzyme Inhibitors; Humans; Imidazoles; L-Lactate Dehydrogenase; Neuroblastoma; Peptide Hydrolases; Piperazines; Proto-Oncogene Proteins c-mdm2; Purines; Roscovitine; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2006 |
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2007 |
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Models, Genetic; Mutation; Piperazines; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2010 |
Inhibitors of the p53-Mdm2 interaction increase programmed cell death and produce abnormal phenotypes in the placozoon Trichoplax adhaerens (F.E. Schulze).
Topics: Animals; Apoptosis; Bromodeoxyuridine; Cell Proliferation; Humans; Imidazoles; In Situ Nick-End Labeling; Phenotype; Piperazines; Placozoa; Protein Binding; Proto-Oncogene Proteins c-mdm2; Purines; Roscovitine; Time Factors; Tumor Suppressor Protein p53 | 2014 |
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Synergism; Humans; Imidazoles; MCF-7 Cells; Melanoma; Mice; Piperazines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Roscovitine; Sulfonamides; Transcription, Genetic; Transfection; Triazines | 2020 |